Shopping Cart
- Remove All
- Your shopping cart is currently empty
Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $239 | In Stock | |
5 mg | $589 | In Stock | |
10 mg | $858 | In Stock |
Description | Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis. |
In vitro | Dupilumab inhibited mRNA expression of T cells, dc, eosinophils, inflammatory pathways and Th2-induced chemokine activation related genes in skin lesions, and showed no activity against IL-17A and significantly decreased IL-22 levels, but 300 mg Dupilumab significantly decreased the expression of IL-17-related genes. Such as elafin (PI3), IL23p19/IL23A and S100A8, and have inhibitory potential (CXCL1 and S100A7). Dupilumab (300 mg) inhibited hyperproliferation-related genes, such as K16, and decreased the expression of S100A, as measured by microarray and qRT-PCR.[1] |
In vivo | In human whole blood, dupilumab inhibits IL-4 and il-13 to stimulate thymus secretion and activates chemokine/chemokine C motif ligand 17 (TARC/CCL17). (Clinical biomarker for atopic dermatitis) with yarnamore potency (50% inhibition at 0.24 to 0.52 nM and 0.26 to 0.27 nM).[1] |
Alias | SAR-231893, REGN-668 |
Cas No. | 1190264-60-8 |
Relative Density. | no data available |
Storage | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.